7 assets in B-Lymphoblastic Leukemia/Lymphoma With IAMP21

Therapeutic assets addressing B-Lymphoblastic Leukemia/Lymphoma With IAMP21, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells B-Lymphoblastic Leukemia/Lymphoma With IAMP21	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit B-Lymphoblastic Leukemia/Lymphoma With IAMP21	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Busulfanum B-Lymphoblastic Leukemia/Lymphoma With IAMP21	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Cyclophosphamide B-Lymphoblastic Leukemia/Lymphoma With IAMP21	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Fludarabine B-Lymphoblastic Leukemia/Lymphoma With IAMP21	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Melphalan B-Lymphoblastic Leukemia/Lymphoma With IAMP21	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Rituximab B-Lymphoblastic Leukemia/Lymphoma With IAMP21	Masonic Cancer Center, University of Minnesota	P2	CCC (53)